Clinical significance of multigene assay in papillary thyroid carcinoma.
10.13201/j.issn.2096-7993.2023.05.011
- Author:
Yuan SHI
1
;
Kai QIAN
1
;
Kai GUO
1
;
Jun LIU
2
;
Zhuoying WANG
1
Author Information
1. Department of Head and Neck Surgery，Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine，Shanghai，200127，China.
2. Department of Otolaryngology，Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.
- Publication Type:Journal Article
- Keywords:
multigene assay;
papillary thyroid carcinoma;
pathological characteristics
- MeSH:
Humans;
Male;
Thyroid Cancer, Papillary/genetics*;
Thyroid Neoplasms/pathology*;
Proto-Oncogene Proteins B-raf/genetics*;
Clinical Relevance;
Carcinoma, Papillary/pathology*;
Mutation
- From:
Journal of Clinical Otorhinolaryngology Head and Neck Surgery
2023;37(5):375-379
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical significance of multigene assay in papillary thyroid carcinoma（PTC）. Methods:Patients who underwent thyroidectomy in a tertiary hospital from August 2021 to May 2022 were enrolled. The eight-gene panel was used to detect the tumor tissue of patients, and the correlation between gene mutations and clinical features was analyzed. Results:Among 161 patients, mutation rate of BRAF V600E, RET/PTC1 and TERT promotor were 82.0%, 6.8% and 4.3%, respectively. BRAF V600E mutation was more common in male patients（P=0.023）. TERT promotor-mutated tumors had a large diameter（P=0.019）, a high proportion of multifocal lesions（P=0.050）, and a large number of lymph node metastases（P=0.031）. Among 89 patients who completed preoperative BRAF detection, there was a strong consistency between the preoperative aspiration test and postoperative panel（Cohen κ=0.694, 95%CI: 0.482-0.906, P<0.01）. In the hematoxylin-eosin sections obtained from 80 patients, BRAF V600E was still the main type of gene mutation, and the classical/follicular type was more distributed. TERT promotor and RET/PTC1 mutation were the main genetic events for tall-cell/columnar/hobnail type and diffuse sclerosing type, respectively. One-way ANOVA showed that there were differences in diagnosis age（P=0.029） and tumor size（P<0.01） among different pathological types. Conclusion:As a simple and feasible clinical detection method for PTC, the multigene assay can supplement the identification of important genetic events other than BRAF V600E, and provide more prognostic information and follow-up hints for postoperative patients.
